DXCM
DEXCOM INC
NASDAQ · Healthcare · Medical - Devices · US
$85.98
−0.07%Year over year
Reported trailing growth
- Revenue
- +15.5%
- EBITDA
- +50.0%
- EBIT
- +65.8%
- EPS
- +76.2%
- Free cash flow
- +146.1%
- Operating cash flow
- +77.0%
Forward estimates
Based on analyst estimates
- Revenue
- +13.6%
- EBITDA
- +12.5%
- EPS
- +13.6%
Three-year CAGR
- Revenue
- +17.0%
- EBITDA
- +33.9%
- EBIT
- +32.6%
- Net income
- +34.8%
- EPS
- +34.5%
- Free cash flow
- +52.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026